reviewed april 2026|next review october 2026|88 physicians psi has verified|2450 published studies
Pentosan Polysulfate (PPS)
Pentosan polysulfate sodium is the only FDA-approved oral treatment for interstitial cystitis, sold as Elmiron since 1996, with a recently identified long-term retinal safety concern that has changed the risk-benefit conversation for chronic use.
Evidence landscape: 2450 published studies
2,450 published items. 18 human studies and 146 animal studies. A well-established compound with an evolving safety profile.
- 18 Human
- 146 Animal
- 36 Reviews
- 2250 Other research
FDA-approved prescription medicine in the United States as Elmiron for interstitial cystitis (painful bladder syndrome).
FDA-approved since 1996 with clinical trial data demonstrating symptom improvement. Post-marketing identification of pigmentary maculopathy with long-term use has prompted updated safety monitoring.
The only FDA-approved oral therapy for interstitial cystitis. A semi-synthetic heparin-like polysaccharide. Also widely used in veterinary medicine for osteoarthritis.
PSI Assessment
One of the few FDA-approved peptide-adjacent therapeutics carries a safety story that has evolved significantly since its original approval. Pentosan polysulfate sodium, sold as Elmiron, has been the only FDA-approved oral treatment for interstitial cystitis since 1996. In recent years, long-term use has been linked to a distinctive retinal maculopathy that was not identified in the original clinical program, fundamentally changing the risk-benefit conversation for chronic use.
The only FDA-approved oral treatment for interstitial cystitis since 1996. A recently identified retinal safety concern has changed the risk-benefit equation for long-term use.
The mechanism is glycosaminoglycan (GAG) layer replenishment in the bladder. In interstitial cystitis, the protective GAG lining of the bladder urothelium is deficient, allowing irritants in urine to reach and inflame the underlying tissue. Pentosan polysulfate is a semi-synthetic heparin-like compound that coats and repairs this damaged lining.
What the evidence supports
FDA-approved for interstitial cystitis as the only oral treatment since 1996. The glycosaminoglycan layer replenishment mechanism is established. Clinical trial data demonstrates symptom improvement. Extensive veterinary use supports chondroprotective properties for osteoarthritis in animal populations.
What is not yet established
Long-term retinal safety, following identification of pigmentary maculopathy with prolonged use that was not detected in the original clinical program. Efficacy for human osteoarthritis (despite strong veterinary evidence). Whether the risk-benefit ratio supports chronic use given the evolving safety profile.
Research Evidence
The findings below cover the approved indication, the evolving safety profile, and the veterinary osteoarthritis evidence.
Evidence by condition
Evidence dimensions across pentosan polysulfate indications. Interstitial cystitis has deep clinical evidence with FDA approval. Osteoarthritis evidence is primarily veterinary.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Interstitial Cystitis | ||||
| Retinal Safety Concern | ||||
| Osteoarthritis (Veterinary) |
FDA-approved for interstitial cystitis based on clinical trials demonstrating symptom improvement in bladder pain, urgency, and frequency. It remains the only oral therapy approved for this indication.
The GAG layer replenishment mechanism provides a targeted approach to a condition with limited treatment options. Symptom improvement is gradual, typically requiring 3-6 months of treatment.
Long-term use has been linked to a distinctive pigmentary maculopathy affecting the retina. This condition was not identified in the original clinical program and was first reported in 2018, more than 20 years after approval.
The maculopathy appears to be dose- and duration-dependent, primarily affecting patients with years of continuous use. Current recommendations include baseline and periodic ophthalmologic screening for patients on long-term therapy.
Extensive veterinary clinical use supports chondroprotective properties for osteoarthritis, with demonstrated effects on proteoglycan synthesis and hyaluronic acid production in joint tissue.
The veterinary evidence base is substantial, but translation to human osteoarthritis has not been validated in controlled trials. The compound is widely used in equine and canine medicine for joint disease.
18 Human|146 Animal|36 Reviews
View all 2450 indexed studiesHow Pentosan Polysulfate (PPS) Works
Pentosan polysulfate sodium is a semi-synthetic sulfated polysaccharide derived from beech tree hemicellulose. It replenishes the deficient GAG layer of the bladder urothelium and has anti-inflammatory, anticoagulant, and chondroprotective properties.
Coats and repairs the damaged bladder lining, reducing pain and urgency.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Semi-synthetic glycosaminoglycan replenishing the deficient GAG layer of bladder urothelium.
What is Pentosan Polysulfate (PPS) being studied for?
Researchers are studying Pentosan Polysulfate (PPS) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Pentosan Polysulfate (PPS) overall. This means a compound can have human studies for one condition but only animal data for another.
Interstitial Cystitis
·FDA ApprovedFDA-approved as the only oral therapy for interstitial cystitis (painful bladder syndrome). Replenishes the deficient GAG layer of the bladder lining, reducing pain, urgency, and frequency.
Limitations: Symptom improvement is gradual (3-6 months). Long-term use linked to retinal maculopathy requiring ophthalmologic monitoring. Not all patients respond to therapy.
Retinal Safety Concern
·FDA ApprovedA distinctive pigmentary maculopathy has been identified with long-term use, first reported in 2018. The condition appears dose- and duration-dependent. Updated safety guidance now recommends baseline and periodic eye examinations.
Limitations: The full scope of the retinal risk is still being characterized. Whether the maculopathy is reversible with drug discontinuation is not fully established. Screening protocols are evolving.
Osteoarthritis (Veterinary)
·Animal StudiesWidely used in veterinary medicine for osteoarthritis in dogs and horses. Chondroprotective mechanisms including proteoglycan synthesis stimulation and hyaluronic acid production are well-characterized in animal models.
Limitations: Human osteoarthritis trials have not been conducted. The veterinary evidence, while substantial, does not directly translate to human clinical practice.
Safety and Regulatory Status
FDA Status: FDA-approved as Elmiron (pentosan polysulfate sodium) for interstitial cystitis since 1996.
Prescription status: Prescription-only in the United States. Oral capsule formulation.
Safety evolution: Post-marketing identification of retinal maculopathy with long-term use has led to updated labeling and screening recommendations.
The most significant safety development is the identification of pigmentary maculopathy with long-term use, first reported in 2018. Baseline and periodic ophthalmologic examinations are now recommended. Other side effects include hair loss (alopecia), diarrhea, nausea, and mild anticoagulant effects.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Pentosan Polysulfate (PPS) discussion.
Comparison and Related Research
Pentosan polysulfate is unique as the only FDA-approved oral therapy for interstitial cystitis. Comparisons are most relevant to other bladder-targeted therapies and chondroprotective compounds.
Head-to-head comparisons
Full research comparisons covering Pentosan Polysulfate (PPS) and another peptide side by side.
Pentosan Polysulfate (PPS) vs BPC-157
Pentosan has specific joint and bladder research. BPC-157 has broad tissue repair evidence. Neither FDA-approved for osteoarthritis. Evidence compared.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Randomized, double-blind trial testing three doses of pentosan polysulfate sodium in patients with interstitial cystitis. The study helped establish dosing parameters for this FDA-approved indication and confirmed symptom improvement in the active treatment groups.Nickel JC et al., 2005 in Urology. View on PubMed
- 2.Pilot study testing whether pentosan polysulfate sodium could reduce osteoarthritis symptoms in the knee. The randomized, placebo-controlled design found improvements in pain and function scores, supporting broader investigation of its chondroprotective properties.Ghosh P et al., 2005 in Curr Ther Res Clin Exp. View on PubMed
- 3.Landmark safety report identifying a unique pattern of retinal damage - pigmentary maculopathy - in patients taking pentosan polysulfate long-term. This was the first publication to formally describe the association between chronic use and a specific type of vision loss.Pearce WA et al., 2018 in Ophthalmology. View on PubMed
- 4.Multicenter study characterizing the range of retinal changes in patients with pentosan polysulfate-associated maculopathy. The findings expanded the known spectrum of the condition and supported the case for routine ophthalmic screening in long-term users.Hanif AM et al., 2019 in JAMA Ophthalmol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.